News Releases

SEATTLE --(BUSINESS WIRE)--Mar. 14, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2018 American Association for Cancer

SEATTLE --(BUSINESS WIRE)--Feb. 27, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at the Cowen 38 th Annual Health Care Conference in

-- Data Presented at 59 th American Society of Hematology Annual Meeting & Exposition -- SEATTLE --(BUSINESS WIRE)--Dec. 9, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today

-- Data Presented at 2017 San Antonio Breast Cancer Symposium -- SEATTLE --(BUSINESS WIRE)--Dec. 6, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results of a

New preclinical data to be presented at multiple upcoming scientific meetings Strong balance sheet with $87.2 million in cash, cash equivalents, and short-term investments SEATTLE --(BUSINESS WIRE)--Nov. 13, 2017-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading immunotherapy company focused

-- Company’s vIgD Platform Well Positioned to Realize Next Generation Immuno-Oncology Therapeutics -- SEATTLE --(BUSINESS WIRE)--Nov. 10, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and

--Poster to be Presented at 2017 ACR/ARHP Annual Meeting-- SEATTLE --(BUSINESS WIRE)--Nov. 6, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced results from preclinical studies

SEATTLE --(BUSINESS WIRE)--Nov. 1, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced the company will present at two upcoming investor conferences in November.

SEATTLE --(BUSINESS WIRE)--Oct. 23, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced it has extended the research term of its worldwide research and license agreement with Kite, a